Search
Batroxobin
go.drugbank.com/drugs/DB09005InvestigationalIn addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. … Recombinant Batroxobin in relatively affordable and could be accessed by mass production.
Categories: Complex MixturesEnrofloxacin
go.drugbank.com/drugs/DB11404InvestigationalVet approvedDue to the identification of fluoroquinolone-resistant strains of _Campylobacter_, in September 2005, the FDA withdrew the approval of enrofloxacin for its use in water to treat flocks of poultry. … Enrofloxacin is an antibiotic agent from the fluoroquinolone family produced by the Bayer Corporation. Enrofloxacin is approved by the FDA for its veterinary use.
D-Proline
go.drugbank.com/drugs/DB02853ExperimentalD-proline is an isomer of the naturally occurring amino acid, L-Proline. D-amino acids have been found in relatively high abundance in human plasma and saliva [A19262].
Idraparinux
go.drugbank.com/drugs/DB06406InvestigationalIdraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.
1alpha,24S-Dihydroxyvitamin D2
go.drugbank.com/drugs/DB06117ExperimentalIt is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.
QR-333
go.drugbank.com/drugs/DB05533InvestigationalQR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder
TBX-3400
go.drugbank.com/drugs/DB17370InvestigationalTBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.
Tecadenoson
go.drugbank.com/drugs/DB04954InvestigationalTecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.
XC221
go.drugbank.com/drugs/DB16503InvestigationalXC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.